Coave Therapeutics announces Positive 12-months Data from Ongoing Phase I/II Clinical Trial of CTx-PDE6b in Patients with Retinitis Pigmentosa Caused

Coave Therapeutics announces Positive 12-months Data from Ongoing Phase I/II Clinical Trial of CTx-PDE6b in Patients with Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b -        CTx-PDE6b demonstrated clinically meaningful benefit in visual functions at the highe...

Related Keywords

Paris ,France General ,France , ,Coave Therapeuticsannounces Positive ,Ongoing Phase ,Retinitis Pigmentosa Caused ,Bi Allelic Mutations ,Retinitis Pigmentosa ,Central Nervous System ,Corrected Visual Acuity ,Visual Field ,Full Field Sensitivity Test ,Optical Coherence Tomography ,